Efficacy and safety of ticagrelor versus prasugrel not affected by eGFR in ACS patients: ISAR-REACT 5 trial

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-01-12T09:00:14+05:30 | Updated On 18 Oct 2023 4:18 PM IST

Listen to this Article

Germany: Results from ISAR-REACT 5 trial have shown that a reduction of estimated glomerular filtration rate (eGFR) is related to increased risk for ischemic and bleeding events in acute coronary syndrome (ACS) patients. However, the reduction had no significant impact on the relative safety and efficacy of ticagrelor versus prasugrel. The study was published in the journal JACC: Cardiovascular Interventions.

Prior to this study, there was no clarity on the outcomes of ticagrelor versus prasugrel in patients with ACS according to eGFR. Jochen Wöhrle, Department of Cardiology and Intensive Care, Medical Campus Lake Constance, Friedrichshafen, Germany, and colleagues therefore aimed to assess the safety and efficacy of ticagrelor versus prasugrel for patients with ACS according to their eGFRs.

The study included 4,012 patients who were then categorized into three groups: low eGFR (<60 mL/min/1.73 m2), intermediate eGFR (≥60 and <90 mL/min/1.73 m2), and high eGFR (≥90 mL/min/1.73 m2). The primary endpoint was a composite of all-cause death, myocardial infarction, and stroke; the secondary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding, both at 1 year.

The research revealed the following findings:

Patients with low eGFRs had a higher risk for the primary endpoint compared with patients with intermediate eGFRs (adjusted HR: 1.89) and those with high eGFRs (adjusted HR: 2.33).
A risk excess for low eGFR was also observed for bleeding (adjusted HR: 1.55 vs intermediate eGFR; adjusted HR: 1.59 vs high eGFR).
However, eGFR did not affect the relative efficacy and safety of ticagrelor versus prasugrel.
In patients with low eGFR, the primary endpoint occurred in 20.5% with ticagrelor and in 14.7% with prasugrel (HR: 1.47); there was no significant difference in bleeding.

The researchers concluded, these results show that among patients with ACS, reduction of eGFR is associated with increased risk for ischemic and bleeding events but has no significant impact on the relative efficacy and safety of ticagrelor versus prasugrel.

Reference:

The study titled, "Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate," is published in the journal JACC: Cardiovascular Interventions.

DOI: https://www.sciencedirect.com/science/article/abs/pii/S193687982101219X

JACCacute coronary syndromeeGFRticagrelorprasugrel

Source : JACC: Cardiovascular Interventions

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751